在周五的研究日,NTSAD首席执行官凯西·弗林(Kathy Flynn)和研究总监瓦莱丽·格雷格(Valerie Greger)博士概述了NTSAD的研究重点和最近的投资。然后,前NTSAD执行董事苏·卡恩(Sue Kahn)主持了“询问行业专家”小组,讨论了Tay-Sachs,Canavan,GM1和Sandhoff疾病的当前研究和药物开发环境。小组成员包括:Aspa Therapeutics的David Rintell,EDD; Azafaros的Gisela Linthorst;内外的泰勒田; JCR USA的Mathias Schmidt,PD博士; Myrtelle的医学博士Olga Flamini;和赛诺菲的克里斯蒂娜·卡多索(Cristina Cardoso)。
• Exceed fundraising goals by securing major gifts, grants, annual appeal donations, sponsorships, and planned giving commitments to meet the annual revenue goal of $1,200,000+ • Cultivate relationships with current and prospective donors and engage with major funders • Implement prospect research, solicitation strategies, and donor stewardship • Plan and execute annual fundraising event, " Imagine & Believe ," and collaborate on other fundraising endeavors •更新和实施NTSAD的开发计划,旨在至少10%的年收入增长•管理捐助者数据和报告,确保准确,及时的沟通•协助委员会参与和董事会报告开发活动